Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis
- PMID: 35948826
- DOI: 10.1111/ijd.16399
Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis
Comment on
-
Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.Br J Clin Pharmacol. 2022 Feb;88(4):1529-1550. doi: 10.1111/bcp.15101. Epub 2021 Nov 2. Br J Clin Pharmacol. 2022. PMID: 34622969
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
